A detailed history of Enclave Advisors LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Enclave Advisors LLC holds 3,550 shares of ABBV stock, worth $830,700. This represents 0.13% of its overall portfolio holdings.

Number of Shares
3,550
Previous 3,557 0.2%
Holding current value
$830,700
Previous $660 Million 24.52%
% of portfolio
0.13%
Previous 0.11%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 14, 2025

SELL
$184.85 - $231.54 $1,293 - $1,620
-7 Reduced 0.2%
3,550 $822 Million
Q2 2025

Jul 17, 2025

BUY
$170.16 - $206.27 $39,987 - $48,473
235 Added 7.07%
3,557 $660 Million
Q1 2025

Apr 10, 2025

SELL
$169.2 - $216.66 $21,996 - $28,165
-130 Reduced 3.77%
3,322 $696 Million
Q4 2024

Jan 16, 2025

BUY
$164.99 - $203.87 $15,839 - $19,571
96 Added 2.86%
3,452 $613 Million
Q3 2024

Nov 12, 2024

BUY
$163.84 - $199.33 $549,847 - $668,951
3,356 New
3,356 $663 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $414B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Enclave Advisors LLC Portfolio

Follow Enclave Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Enclave Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Enclave Advisors LLC with notifications on news.